--TransCode Therapeutics, Inc., the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for 2023 and recent business progress..

BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today ...

TransCode Therapeutics Inc RNAZ shares are trading lower by 16% to 29 cents during Monday’s session after the company announced a 1-for-33 reverse stock split.. What Else: Under the split, every ...

As of April 2025, TransCode reported a cash balance of $5.81 million, with total liabilities exceeding assets by $2.02 million. Recent fundraising has helped shore up liquidity, ...

TransCode Therapeutics, Inc. BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of ...

TransCode Therapeutics Inc (NASDAQ: RNAZ) shares are trading higher Thursday after the company announced it received written authorization from the FDA to proceed with its ...

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology. PRESS RELEASE GlobeNewswire . Oct. 10, 2024, 07:00 AM.

This is one reason why TransCode Therapeutics’ stock is falling today. On top of that, the public offering price is a significant discount over its prior closing price of 79 cents.